...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Circulating CD14++CD16+ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis
【24h】

Circulating CD14++CD16+ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis

机译：循环CD14 ++ CD16 + 单核细胞亚群是糖皮质激素治疗心脏结节病患者疗效的替代指标

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: We aimed to evaluate whether specific monocyte subsets could serve as surrogate markers of disease activity in cardiac sarcoidosis (CS) evaluated by 18F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET). Methods?and?Results: We studied 28 patients with CS (8 men; mean age: 61±9 years) diagnosed according to consensus criteria. We divided the patients into 2 groups: known CS receiving corticosteroid therapy (Rx(+); n=13) and new-onset CS (Rx(?); n=15), and analyzed 3 distinct monocyte subsets (CD14+CD16?, CD14++CD16+, and CD14+?CD16+). Monocyte subsets were also analyzed in 10 Rx(?) patients before and 12 weeks after starting corticosteroid therapy. Inflammatory activity was quantified by 18F-FDG PET using the coefficient of variation (COV) of the standardized uptake value (SUV). The proportion of CD14++CD16+monocytes in Rx(+) patients (10.8 [0.2–23.5] %) was significantly lower than in Rx(?) patients (23.0 [11.5–38.4] %, P=0.001). After corticosteroid therapy, the COV of the SUV was significantly improved from 0.32 [0.14–0.62] to 0.17 [0.04–0.43] (P=0.017). The proportion of CD14++16+monocytes showed a significant decrease from 22.2 [8.8–38.4] % to 8.4 [1.8–16.8] % (P=0.001). The decrease in the proportion of CD14++16+monocytes significantly correlated with the decrease in the COV of the SUV (r=0.495, P=0.027). Conclusions: CD14++16+monocytes are a possible surrogate marker of the therapeutic effect of corticosteroid therapy in CS. ( Circ J 2015; 79: 1585–1592)
机译：背景：我们旨在评估通过 18 F-氟-2-脱氧葡萄糖正电子发射断层显像（ 18 <”对心脏结节病（CS）中特定的单核细胞亚群是否可以作为疾病活动的替代指标。 / sup> F-FDG PET）。方法和结果：我们研究了根据共识标准诊断的28例CS患者（8例男性，平均年龄：61±9岁）。我们将患者分为两组：已知的接受皮质类固醇治疗的CS（Rx（+）; n = 13）和新发的CS（Rx（？）; n = 15），并分析了3个不同的单核细胞亚群（CD14 + CD16 ？，CD14 ++ CD16 + 和CD14 +？ CD16 + ）。在开始糖皮质激素治疗之前和之后12周，对10名Rx（？）患者的单核细胞亚群也进行了分析。使用标准摄取值（SUV）的变异系数（COV），通过 18 F-FDG PET量化炎症活性。 Rx（+）患者中CD14 ++ CD16 + 单核细胞的比例（10.8 [0.2–23.5]％）显着低于Rx（？）患者（23.0） [11.5–38.4]％，P = 0.001）。糖皮质激素治疗后，SUV的COV从0.32 [0.14-0.62]显着提高到0.17 [0.04-0.43]（P = 0.017）。 CD14 ++ 16 + 单核细胞的比例从22.2 [8.8-38.4]％降至8.4 [1.8-16.8]％（P = 0.001）。 CD14 ++ 16 + 单核细胞比例的下降与SUV的COV下降显着相关（r = 0.495，P = 0.027）。结论：CD14 ++ 16 + 单核细胞可能是皮质类固醇激素治疗CS的可能替代指标。 （Circ J 2015; 79：1585–1592）

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号